Investors

Press Releases

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Press Releases

Enveric Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022

August 31, 2022

Enveric Biosciences Appoints New Independent Directors

July 27, 2022

Enveric Biosciences Announces Closing of $8 Million Registered Direct and Private Placement Offerings, Priced at a Premium to Market Under Nasdaq Rules

July 26, 2022

Enveric Biosciences Announces $8 Million Registered Direct Offering and Private Placement, Priced at a Premium to Market Under Nasdaq Rules

July 25, 2022

Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines

July 19, 2022

Enveric Biosciences Announces Reverse Stock Split

July 14, 2022

Enveric Biosciences Advances Drug Development for Mental Health Indications and Intellectual Property Portfolio

July 13, 2022

Enveric Biosciences to Participate in Upcoming Conferences in June 2022

June 8, 2022

Enveric Biosciences to Participate in the Microdose Psychedelic Capital Conference on May 26, 2022

May 24, 2022

Enveric Biosciences to Participate in the H.C. Wainwright Global Investment Conference on May 23-26, 2022

May 17, 2022

‹
1
…
6
7
8
9
10
…
13
›

Company

Team

Psybrary™

Pipeline

Investors

Contact

Sign Up for Updates

© 2024 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.